EC approves Exelixis' Cometriq

The European Commission conditionally approved an MAA for Cometriq cabozantinib from Exelixis Inc. (NASDAQ:EXEL) to treat progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Exelixis already markets the spectrum-selective kinase inhibitor of VEGF receptor 2 ( KDR/Flk-1; VEGFR-2) and c-Met receptor tyrosine kinase for the indication in the U.S. Under a 2013 deal, Swedish Orphan Biovitrum AB (SSE:SOBI) will commercialize Cometriq for MTC in the EU through the end of 2015. ...